Gene therapy aims to bring back light sensitivity in fading eyes

NCT ID NCT04278131

Recruiting now Disease control Sponsor: Bionic Sight LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a gene therapy called BS01 for people with retinitis pigmentosa, an inherited eye disease that causes gradual vision loss. The therapy delivers a light-sensitive protein to cells in the retina, aiming to help them detect light again. Twenty participants with severe vision loss will be monitored for safety and any improvement in light, motion, or shape detection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BS01 (a gene therapy that makes eye cells sensitive to light)
What this could lead to: If it works, this could help people with retinitis pigmentosa regain some ability to detect light, motion, and shapes.
What could go wrong: This is an early-phase trial with only 20 people, so results may not apply to everyone. Gene therapies can cause inflammation or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINITIS PIGMENTOSA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

New Jersey Retina
RECRUITING

Teaneck, New Jersey, 07666, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.